Navigation Links
Indiana University neuroscientists map a new target to wipe pain away

INDIANAPOLIS Researchers at the Indiana University School of Medicine have discovered a peptide that short circuits a pathway for chronic pain. Unlike current treatments this peptide does not exhibit deleterious side effects such as reduced motor coordination, memory loss, or depression, according to an article in Nature Medicine posted online June 5, 2011.

The peptide, CBD3, has been shown in mice to interfere with signals that navigate calcium channels to produce pain. Unlike other substances that block pain signals, CBD3 does not directly inhibit the influx of calcium. This is important as influx of calcium regulates heart rhythm and vital functions in other organs.

Rajesh Khanna, Ph.D., assistant professor of pharmacology and toxicology at the Indiana University School of Medicine, said the peptide discovered by him and his colleagues is potentially safer to use than addictive opioids or cone snail toxin Prialta recognized analgesic that is injected into the spinal column, both of which can cause respiratory distress, cardiac irregularities and other problems.

"After opioidsthe gold standard for pain control -- the next target is calcium channels," said Dr. Khanna. "Along the pain pathway in the spinal cord, there are pain-sensing neurons called nociceptors that have an abundance of calcium channels."

Earlier international research has shown that the calcium channel is a key player within the pathway for pain signals. Based on work from Dr. Khanna's laboratory, it is also accepted that an axonal protein, CRMP-2, binds to the calcium channel "acting like a remote control" to modulate transmission of excitability and pain signals, Dr. Khanna explained.

He and his colleagues discovered the CBD3 peptide, a portion of the CRMP-2 protein, realizing that its smaller size would be beneficial in producing a synthetic version for drug development.

CBD3 can be given systemically and blocks pain in a variety of acute as well as chronic pain models, he said. The novel peptide binds to the calcium channel and reduces the number of excitability signals without disrupting the beneficial global calcium flow. Upon reaching the brain, these signals are interpreted as the sensation of pain.

"Since our approach does not directly inhibit calcium entry through voltage-gated channels, we expect that this molecule will be more specific and have fewer side effects than currently available analgesics," said Dr. Khanna. "We anticipate that this peptide will serve as a novel pharmacological therapeutic for the relief of chronic pain."


Contact: Mary L. Hardin
Indiana University School of Medicine

Related medicine news :

1. Indiana U. study points to health disparities in physical fitness
2. A safer, more effective morphine may be possible with Indiana University discovery
3. Grant launches cervical cancer-free Indiana initiative
4. APHA 2010: Study finds funding for substance abuse in Indiana lacking
5. Indianapolis to host international conference on frontotemporal dementias
6. NRPA Launches National Hunger Relief Initiative at Indianapolis' Douglass Park
7. Indiana Home and Hospice Care Foundation Selects Pearson to Bolster Workforce Training Initiatives
8. National Insurance Company Looks to Indianapolis-based TriDigital Solutions for Affordable CD Replication and Mailing Project
9. Indiana Boudoir Photographer Begins Shooting Breast Cancer Charity Calendar
10. Indiana Paging Network and Onset Technology Partner to Deliver Paging Messages to Blackberry Smartphones
11. Indianapolis Cosmetic Surgeon One of Few in Indiana Offering Patients Large Volume Liposuction, Brazilian Butt Lift
Post Your Comments:
Related Image:
Indiana University neuroscientists map a new target to wipe pain away
(Date:12/1/2015)... ... 01, 2015 , ... The workstation boundaries for imaging specialists ... Systems launches MED-TAB™ -- the world’s first portable DICOM-calibrated medical image display, debuting ... December 4, 2015. , MED-TAB is expected to change teleradiology because for ...
(Date:12/1/2015)... IL (PRWEB) , ... December 01, 2015 , ... ... keeping their independence is everything. That is why Hollister Incorporated has launched the ... to offer this next product in the VaPro touch free catheter portfolio,” said ...
(Date:12/1/2015)... ... December 01, 2015 , ... McLean, VA., ... awarded a fixed price per sprint agile development contract to support the National ... over five years, provides software engineering, infrastructure, as well as operations and sustainment ...
(Date:12/1/2015)... ... December 01, 2015 , ... XTC Semifinals 2016 - ... to head to Las Vegas for CES 2016, the world’s largest Consumer Electronic Show, ... Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica Serra, and venture capitalist ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Arash ... Modern Man for 2015. , Angeleno Magazine is a division of Modern ... in 1994, Modern Luxury includes more than 50 magazine titles across 15 major ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... VIEJO, Calif. , Dec. 1, 2015 /PRNewswire/ ... the prevalence of symptoms for pseudobulbar affect (PBA), ... outbursts of laughing and/or crying resulting from certain ... use of antipsychotic medications in nursing home residents, ... Geriatric Psychiatry. The study showed that almost one ...
(Date:12/1/2015)... 1, 2015 ... of the  "2016 Shigella Testing Market: ... Competitive Strategies, Emerging Opportunities--US, Europe (France, ... to their offering. --> ... of the  "2016 Shigella Testing Market: ...
(Date:11/30/2015)... BASEL, Switzerland , Dec. 1, 2015 ... through its wholly-owned UK subsidiary Proximagen Ltd., today announced ... novel, oral small molecule inhibitor of Vascular Adhesion Protein ... in the treatment of inflammatory disease. The VAP-1 inhibitor ... --> --> Under the terms ...
Breaking Medicine Technology: